Financial Data and Key Metrics Changes - The combined net revenues from the portfolio of FDA-approved brands totaled $9.1 million during Q2 2021, a slight decline from the prior year period, but net revenues for the first six months of 2021 were $19.6 million, up 9.3% compared to the same period in 2020 [13][44] - The company posted a profit of $1.4 million during the first half of 2021, a significant turnaround from the $2 million loss during the same period last year [16] - Cash flow from operations totaled $4.5 million year-to-date, up from $3.7 million in the first half of last year [16][46] - Total operating expenses for Q2 2021 were $10.5 million, down from $11.2 million during the prior year period [46] Business Line Data and Key Metrics Changes - Kristalose generated $5.3 million in revenue during Q2 2021, with a total of $8.3 million for the first half of the year, reflecting a 22% increase over the same period last year [15][45] - Vibativ sales grew 21% over the same period last year, contributing $1.8 million in Q2 2021 and $6.9 million in the first half of 2021 [26][45] - Caldolor generated $0.9 million in Q2 2021 and $2.5 million in the first half of 2021 [44][45] - Vaprisol contributed $0.4 million in Q2 2021 and $1.5 million in the first half of 2021 [44][45] Market Data and Key Metrics Changes - The company continues to face headwinds due to the pandemic, impacting several brands, but has a diversified product portfolio that has shown strong performance [11][12] - The performance of key promoted brands has continued to show favorable prescription trends, although reported revenues can fluctuate due to wholesaler buying patterns [14] Company Strategy and Development Direction - The company is focused on building a diversified portfolio of innovative products through a multifaceted strategy that includes the development of new candidates and the acquisition of established brands [57] - The company is preparing for the launch of RediTrex, a new line of injectable methotrexate products, with a full national launch scheduled for late September 2021 [40][58] - Cumberland is also sponsoring three key Phase II clinical programs for its ifetroban product candidates, targeting large potential markets [22][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced during the pandemic but expressed optimism about the company's ability to deliver meaningful revenue growth in 2021 [56][59] - The company remains dedicated to advancing patient care and delivering high-quality medicines, adapting market strategies and promotional activities to support customers and patients [59] Other Important Information - The company reported total assets of $88.9 million, liabilities of $41 million, and shareholders' equity of $48 million as of June 30, 2021 [50] - The company received a paycheck protection loan of $2.2 million, which was fully forgiven, allowing the company to avoid layoffs during the pandemic [51][52] Q&A Session Summary - No specific questions or answers were documented in the provided content, as the call concluded with an invitation for private discussions with management [60][61]

Business Focus and Product Development - Cumberland Pharmaceuticals focuses on acquiring, developing, and commercializing branded prescription products in hospital acute care, gastroenterology, and rheumatology markets[66]. - The company has seven FDA-approved products, including Acetadote and Caldolor, and is expanding its portfolio through clinical trials and acquisitions[69]. - Cumberland's ifetroban product candidates are undergoing Phase II clinical programs for conditions such as Duchenne Muscular Dystrophy and Systemic Sclerosis[93]. - Cumberland is exploring new product development opportunities, including a cholesterol-reducing agent for hospital use, which has completed Phase I and II studies[97][98]. - The company is actively pursuing international partnerships to expand the availability of its products in global markets[75]. Financial Performance - Net revenues for the three months ended March 31, 2021, were $10.5 million, an increase of $2.2 million (26.5%) compared to $8.3 million for the same period in 2020[103]. - Vibativ revenue increased by $2.6 million (108%) to $5.1 million for the three months ended March 31, 2021, driven by increased net pricing and improved sales volumes[103]. - Caldolor revenue rose by $0.4 million (40.4%) to $1.5 million, attributed to increased international shipments and improved net pricing[105]. - Operating income improved by $1.5 million, resulting in a loss of $324,300 for the first quarter of 2021 compared to a loss of $1.8 million in the same period last year[103]. - Cash provided by operating activities was $1.8 million for the three months ended March 31, 2021, compared to $0.9 million in the same period last year[109]. Cost Management and Expenses - Cost of products sold was $2.4 million for Q1 2021, representing 22.9% of net revenues, up from 19.6% in Q1 2020[105]. - General and administrative expenses increased to $2.2 million from $2.0 million, primarily due to higher professional, legal, and insurance costs[105]. Financial Position and Liquidity - The company had approximately $44 million of net operating loss carryforwards as of March 31, 2021, expected to offset future income tax obligations[107]. - Working capital increased to $26.5 million as of March 31, 2021, compared to $24.3 million as of December 31, 2020[109]. - The current ratio improved to 2.2 as of March 31, 2021, compared to 1.9 as of December 31, 2020[109]. - The company entered into a Fourth Amendment to the Revolving Credit Loan Agreement with Pinnacle Bank, extending the maturity date through October 1, 2022, with a principal available for borrowing of up to $15 million, potentially expandable to $20 million[112]. - As of March 31, 2021, the company had $15.0 million in borrowings outstanding under its revolving credit facility, with an applicable interest rate of 3.65%[116]. COVID-19 Response - The company received a Paycheck Protection Program loan of $2,187,140 to maintain payroll and operations during the COVID-19 pandemic[88]. - The company received a Paycheck Protection Program loan of $2,187,140 from Pinnacle Bank, which was used for qualifying expenses, and has not laid off or furloughed any employees due to the COVID-19 pandemic[113][114]. - Cumberland's Vibativ product has been used to treat COVID-19 patients with secondary bacterial pneumonia, demonstrating its effectiveness in critical care settings[84]. Risk Management - The interest rate spread under the Fourth Amendment of the Pinnacle Agreement is between 1.75% to 2.75% above LIBOR, with a minimum LIBOR of 0.90%[116]. - The company believes its interest rate risk related to cash and cash equivalents is not material, and current interest rates do not expose it to significant downside risk[116]. - The company does not utilize financial instruments to hedge foreign currency fluctuations, and its exposure is considered minimal[117]. - Foreign currency exchange gains and losses were immaterial for the three months ended March 31, 2021, and a 5% change in exchange rates would not materially affect operating results[117]. - The company was in compliance with the Tangible Capital Ratio financial covenant as of March 31, 2021, and expects to maintain compliance in future periods[112].

CUMBERLAND® PHARMACE UTICALS Corporate Presentation Nasdaq CPIX Safe Harbor Statement This presentation contains forward-looking statements concerning our approved products and product development, our technology, our competitors, our intellectual property, our financial condition and our plans for research and development programs that involve risks, uncertainties and assumptions. These statements are based on the current estimates and assumptions of the management of Cumberland Pharmaceuticals as of the d ...

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Q1 2021 Earnings Conference Call May 11, 2021 4:30 PM ET Corporate Participants Erin Gull - Corporate Relations Manager A. J. Kazimi - Chairman and Chief Executive Officer Marty Cearnal - President and Chief Commercial Officer Michael Bonner - Chief Financial Officer Conference Call Participants Operator Thank you for joining Cumberland Pharmaceuticals First Quarter 2021 Financial Report and Company Update. This call is being recorded at the company's request a ...

Part I [Business](index=4&type=section&id=Item%201.%20Business%2E) Cumberland Pharmaceuticals specializes in acquiring, developing, and commercializing branded prescription products for hospital acute care, gastroenterology, and rheumatology - The company's primary target markets are **hospital acute care, gastroenterology, and rheumatology**, which are addressed by small, targeted sales forces[10](index=10&type=chunk) - The COVID-19 pandemic created headwinds by reducing hospital admissions and elective surgeries, which impacted revenues. However, the company's **diversified product portfolio** provided some resilience[18](index=18&type=chunk) Portfolio of FDA Approved Brands | Product | Indication | | :--- | :--- | | Acetadote® | Acetaminophen Poisoning | | Caldolor® | Pain and Fever | | Kristalose® | Chronic and Acute Constipation | | Omeclamox®-Pak | H. pylori infection and related Duodenal Ulcer disease | | Vaprisol® | Euvolemic and Hypervolemic Hyponatremia | | Vibativ® | Serious bacterial infections | | RediTrex® | Arthritis and psoriasis | - The company's growth strategy focuses on maximizing existing brands, acquiring new products, advancing its clinical pipeline, leveraging co-promotion partnerships, and expanding internationally[14](index=14&type=chunk)[75](index=75&type=chunk) [Products](index=6&type=section&id=Products) The company markets seven FDA-approved products, including Acetadote, Caldolor, Vibativ, and RediTrex, with Omeclamox-Pak currently unavailable - Acetadote® and its Authorized Generic, both using an EDTA-free formulation, maintained a **significant market share in 2020**. The product's patent is upheld until **August 2025**[24](index=24&type=chunk)[26](index=26&type=chunk) - A full-scale launch of the new ready-to-use Caldolor® product began in January 2020 but was impacted by the **COVID-19 pandemic** and the postponement of elective surgeries[36](index=36&type=chunk) - Demand for Vibativ® grew in 2020, as it was used to treat pneumonia from secondary bacterial infections in hospitalized **COVID-19 patients**[57](index=57&type=chunk) - The packager for Omeclamox®-Pak suspended operations in 2020 due to financial difficulties, leading to the product being **currently unavailable**. The FDA has been notified[51](index=51&type=chunk) - RediTrex®, for arthritis and psoriasis, received FDA approval in December 2019 and began initial shipments in November 2020, with a national launch planned for the **second half of 2021**[60](index=60&type=chunk) [Pipeline](index=10&type=section&id=Pipeline) The pipeline focuses on ifetroban candidates in Phase II for AERD, SSc, and DMD, with enrollment slowed by COVID-19 - The clinical pipeline is focused on **ifetroban**, with Phase II programs for Aspirin-Exacerbated Respiratory Disease (AERD), Systemic Sclerosis (SSc), and Duchenne Muscular Dystrophy (DMD)[62](index=62&type=chunk)[65](index=65&type=chunk)[70](index=70&type=chunk) - The Phase II study for ifetroban in DMD is supported by **over $1 million in funding** from the FDA's Orphan Drug Grant program[70](index=70&type=chunk) - Clinical trial enrollment was **significantly slowed during 2020** due to the COVID-19 pandemic, but many study sites have since reopened[61](index=61&type=chunk)[112](index=112&type=chunk) - A Phase II study for a new hospital-based cholesterol-reducing agent has completed patient enrollment, and the company has filed the study report with the FDA[73](index=73&type=chunk)[114](index=114&type=chunk) [Sales, Marketing, and Customers](index=13&type=section&id=Sales%2C%20Marketing%2C%20and%20Customers) Cumberland employs two sales forces targeting hospitals and specialists, with three major distributors accounting for 71% of 2020 gross revenues - The company operates two specialized sales forces: a hospital division and a field sales team for gastroenterology and rheumatology, totaling approximately **50 representatives and managers**[82](index=82&type=chunk)[83](index=83&type=chunk)[85](index=85&type=chunk) 2020 Revenue Concentration by Customer | Customer | Percentage of Gross Revenue | | :--- | :--- | | Customer 1 | 25% | | Customer 2 | 25% | | Customer 3 | 21% | [Patents, Trademarks and Other Intellectual Proprietary Rights](index=21&type=section&id=Patents%2C%20Trademarks%20and%20Other%20Intellectual%20Proprietary%20Rights) The company protects products via patents and trademarks, with key patents for Acetadote and Caldolor extending to 2025-2032 - A series of patents protect the Acetadote® EDTA-free formulation, with the '445 patent expiring in **August 2025** and the '356 patent expiring in **May 2026**. The company has successfully defended the '445 patent in court, securing an injunction against a generic version until 2025[152](index=152&type=chunk)[160](index=160&type=chunk)[168](index=168&type=chunk) - Caldolor® is protected by numerous patents, including formulation patent '286 (expiring **Nov 2021**) and several method-of-use patents expiring between **2029 and 2032**[172](index=172&type=chunk)[173](index=173&type=chunk)[176](index=176&type=chunk) - Vibativ® is protected by eleven patents listed in the FDA Orange Book, including a composition of matter patent ('623) that expires in **January 2027**[182](index=182&type=chunk) - The company has **no issued patents** for its RediTrex, Omeclamox-Pak, and Kristalose products[183](index=183&type=chunk) [Competition](index=25&type=section&id=Competition) Cumberland faces intense competition from branded, generic, and alternative treatments across its Acetadote, Caldolor, and Vibativ portfolios - Acetadote® competes with generic injectable products, including an Authorized Generic version of its own EDTA-free formulation distributed by Perrigo, and older formulations containing EDTA from competitors like Akorn and Fresenius Kabi[189](index=189&type=chunk)[190](index=190&type=chunk) - Caldolor®'s primary competitors in the acute pain market include generic injectable opioids, ketorolac, and branded non-narcotic analgesics such as Mallinckrodt's Ofirmev® (IV acetaminophen) and Baudax Bio's Anjeso™ (IV meloxicam)[191](index=191&type=chunk)[192](index=192&type=chunk) - Vibativ® faces competition from major generic antibiotics like vancomycin, linezolid, and daptomycin, as well as newer branded agents including Teflaro®, Dalvance®, and Orbactiv®[206](index=206&type=chunk)[207](index=207&type=chunk) [Risk Factors](index=36&type=section&id=Item%201A.%20Risk%20Factors%2E) The company faces risks from COVID-19, third-party manufacturing, competition, regulation, IP, and financial volatility - The COVID-19 pandemic has **adversely impacted the business** by disrupting day-to-day activities, limiting sales force access to medical facilities, and potentially causing revenue loss and supply interruptions[278](index=278&type=chunk)[280](index=280&type=chunk) - The company is highly dependent on **third-party manufacturers** for all its products. Any failure by these suppliers to produce sufficient quantities or comply with GMP regulations could lead to product shortages and lost revenue. The packager for Omeclamox-Pak suspended operations due to COVID-19's financial impact[288](index=288&type=chunk)[289](index=289&type=chunk)[294](index=294&type=chunk) - Competition from generic equivalents poses a **significant threat**. The introduction of a generic can lead to a substantial loss in revenues for a branded product[306](index=306&type=chunk)[308](index=308&type=chunk) - The company's strategy of acquiring products has resulted in significant intangible assets (**29% of total assets** as of Dec 31, 2020), which are subject to amortization and potential impairment, potentially harming operating results[419](index=419&type=chunk)[420](index=420&type=chunk) - As of December 31, 2020, officers and directors control approximately **41% of the company's common stock**, allowing them to significantly influence corporate actions[437](index=437&type=chunk) [Properties](index=60&type=section&id=Item%202.%20Properties%2E) Cumberland leases its Nashville headquarters and a subsidiary's office/lab space, relying on third-party manufacturers - The company leases approximately **25,500 sq. ft.** for its corporate headquarters in Nashville, TN, with the lease expiring in **October 2022**[461](index=461&type=chunk) - Its subsidiary, CET, leases approximately **14,200 sq. ft.** of office and lab space in Nashville, TN, through **April 2023**, with an option to extend to 2028[462](index=462&type=chunk) [Legal Proceedings](index=60&type=section&id=Item%203.%20Legal%20Proceedings%2E) Legal proceedings, particularly Acetadote patent defense, are referenced from the Business section - Information regarding legal proceedings, particularly concerning Acetadote patent defense, is incorporated by reference from the Business section (Part 1, Item 1)[463](index=463&type=chunk) Part II [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=60&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities%2E) Cumberland's common stock trades on Nasdaq, with no cash dividends paid, and a share repurchase program active in 2020 - The company's common stock trades on the **Nasdaq Global Select Market** under the symbol **CPIX**[465](index=465&type=chunk) - The company has a **$10.0 million share repurchase program** and repurchased **503,626 shares** for approximately **$1.8 million** during the year ended December 31, 2020[469](index=469&type=chunk) Share Repurchases in Q4 2020 | Period | Total Shares Purchased | Average Price Paid per Share ($) | | :--- | :--- | :--- | | October | 38,501 | $3.14 | | November | 31,162 | $3.02 | | December | 26,280 | $3.06 | | **Total** | **95,943** | | [Selected Financial Data](index=62&type=section&id=Item%206.%20Selected%20Financial%20Data%2E) The company reported increased net revenues in 2020 but continued operating and net losses, with total assets and equity declining Selected Historical Financial Data (in thousands, except per share data) | Metric | 2020 | 2019 | 2018 | | :--- | :--- | :--- | :--- | | Net revenues | $37,441 | $34,388 | $29,345 | | Operating income (loss) | $(6,382) | $(9,288) | $(11,173) | | Net income (loss) from continuing operations | $(6,626) | $(9,212) | $(10,821) | | Net income (loss) attributable to common shareholders | $(3,339) | $(3,538) | $(6,963) | | Earnings (loss) per share – diluted | $(0.22) | $(0.23) | $(0.45) | | Total assets | $96,463 | $104,549 | $112,694 | | Total equity | $46,873 | $51,085 | $55,571 | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=63&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations%2E) Net revenues increased by 8.9% in 2020, narrowing the operating loss, while liquidity remained solid with positive cash from operations [Results of Operations](index=68&type=section&id=Results%20of%20Operations) Net revenues rose 8.9% to $37.4 million in 2020, driven by Kristalose and Vibativ, improving the operating loss Net Revenues by Product (2020 vs. 2019, in thousands) | Product | 2020 | 2019 | Change | | :--- | :--- | :--- | :--- | | Kristalose | $15,568 | $12,895 | $2,673 | | Vibativ | $10,871 | $8,692 | $2,179 | | Caldolor | $5,337 | $5,222 | $115 | | Acetadote | $1,874 | $3,824 | $(1,950) | | Omeclamox-Pak | $257 | $838 | $(581) | | Vaprisol | $1,077 | $937 | $140 | | RediTrex | $857 | $0 | $857 | | **Total Net Revenues** | **$37,441** | **$34,388** | **$3,053** | - Operating loss for 2020 improved to **$(6.4) million** from **$(9.3) million** in 2019, a change of **$2.9 million**, driven by revenue growth and cost management[508](index=508&type=chunk) - Cost of products sold as a percentage of net revenues increased from **21.6% in 2019 to 23.1% in 2020**, mainly due to a shift in product mix towards Vibativ, which has a higher cost basis due to purchase accounting[516](index=516&type=chunk) - Selling and marketing expenses decreased by **$0.5 million** in 2020 due to lower promotional spending and travel, while R&D costs decreased by **$1.1 million** due to reduced study activity[517](index=517&type=chunk)[518](index=518&type=chunk) [Liquidity and Capital Resources](index=73&type=section&id=Liquidity%20and%20Capital%20Resources) Cash and equivalents decreased to $24.8 million in 2020, with positive operating cash flow and a $15 million credit facility Liquidity Summary (as of Dec 31) | Metric | 2020 | 2019 | | :--- | :--- | :--- | | Cash and cash equivalents ($) | $24,753,796 | $28,212,635 | | Working capital ($) | $24,302,146 | $26,012,840 | | Revolving line of credit availability ($) | $0 | $1,500,000 | Summary of Cash Flows (Year ended Dec 31) | Activity | 2020 | 2019 | | :--- | :--- | :--- | | Operating activities ($) | $5,415,061 | $3,056,356 | | Investing activities ($) | $(1,757,789) | $2,297,848 | | Financing activities ($) | $(7,116,111) | $(5,080,529) | - In April 2020, the company received a **$2,187,140 loan** under the Paycheck Protection Program (PPP) and submitted a request for forgiveness in October 2020[549](index=549&type=chunk)[744](index=744&type=chunk) - The company has a revolving credit agreement with Pinnacle Bank, extended through **October 2022**, with up to **$15 million available**. As of Dec 31, 2020, **$15.0 million was outstanding**[545](index=545&type=chunk)[737](index=737&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=77&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk%2E) The company faces interest rate risk from its variable-rate credit facility but minimal foreign currency risk - The company has interest rate risk from its revolving line of credit, which is based on LIBOR plus a spread of **1.75% to 2.75%**. As of Dec 31, 2020, **$15.0 million was outstanding**[565](index=565&type=chunk) - Foreign currency exchange rate risk is considered minimal as operations are primarily in the U.S. and foreign currency transactions are limited[566](index=566&type=chunk)[567](index=567&type=chunk) [Controls and Procedures](index=77&type=section&id=Item%209A.%20Controls%20and%20Procedures%2E) Disclosure controls and internal control over financial reporting were deemed effective as of December 31, 2020 - Management concluded that as of December 31, 2020, the company's disclosure controls and procedures were **effective**[571](index=571&type=chunk) - Based on the COSO framework, management concluded that internal control over financial reporting was **effective** as of December 31, 2020[610](index=610&type=chunk)[611](index=611&type=chunk) [Other Information](index=78&type=section&id=Item%209B.%20Other%20Information%2E) New employment agreements for key executive officers, effective January 2021, updated base salaries and covenants - New employment agreements were executed for key officers, including the CEO, CCO, CDO, and CFO, effective **January 1, 2021**[574](index=574&type=chunk)[575](index=575&type=chunk) - The new agreement for CEO A.J. Kazimi sets his base salary at **$610,132**[576](index=576&type=chunk) Part III [Part III](index=79&type=section&id=PART%20III) Information for Part III (Items 10-14) is incorporated by reference from the company's 2021 proxy statement - Information for Part III (Items 10-14) is incorporated by reference from the registrant's Proxy Statement for its **2021 annual meeting of shareholders**[587](index=587&type=chunk) Part IV [Part IV](index=80&type=section&id=PART%20IV) [Exhibits, Financial Statement Schedules](index=80&type=section&id=Item%2015.%20Exhibits%2C%20Financial%20Statement%20Schedules%2E) This section lists all documents filed as part of the Form 10-K report, including financial statements and exhibits - This section contains the list of financial statements, schedules, and exhibits filed with the Form 10-K[591](index=591&type=chunk)

Financial Data and Key Metrics Changes - For Q4 2020, net revenues from continuing operations were $10.3 million, a 10% increase from $9.3 million in the prior year period [25] - Full year 2020 net revenues were $37.4 million, an 8.9% increase over the prior year [26] - Adjusted earnings for Q4 were $0.2 million, or $0.01 per share, a significant turnaround from a loss of $1.9 million, or $0.12 per share, during the prior year period [29] - Adjusted earnings for the full year were a loss of $0.1 million, or $0.01 per share, compared to a loss of $3.4 million, or $0.22 per share, in the prior year [30] Business Line Data and Key Metrics Changes - Q4 revenues by product included $5.2 million for Kristalose, $2.3 million for Vibativ, $1.7 million for Caldolor, and $0.9 million for RediTrex [26] - Annual 2020 net revenues by products included $15.6 million for Kristalose, $10.9 million for Vibativ, $5.3 million for Caldolor, and $0.9 million for RediTrex [27] - Vibativ has been a significant contributor, delivering a total cash contribution of $18 million since its launch in late 2018 [31] Market Data and Key Metrics Changes - The company faced challenges due to the pandemic, impacting hospital admissions and physician office visits, but managed to mitigate the impact through a diverse product portfolio [9] - The introduction of the next-generation Caldolor product was affected by the pandemic, but is expected to perform better as elective surgeries resume [17] Company Strategy and Development Direction - The company aims to expand its product portfolio through business development initiatives and currently features seven FDA-approved brands with a robust pipeline [40] - The focus is on maximizing the potential of existing brands while adding differentiated products [41] Management's Comments on Operating Environment and Future Outlook - Management expressed gratitude for maintaining operations and organizational integrity during 2020 despite challenges [39] - The company is optimistic about future growth opportunities from products like Vibativ and RediTrex, with expected sales potential of $20 million to $30 million for Vibativ and $30 million to $40 million for RediTrex over the next several years [48] Other Important Information - The company ended 2020 with over $96 million in total assets, including $24.8 million in cash and equivalents [35] - The company received a $2.2 million loan under the paycheck protection program, which helped prevent employee layoffs during the pandemic [36] Q&A Session Summary Question: Where are the greatest opportunities for revenue growth? - Management highlighted significant growth opportunities in Kristalose, Vibativ, Caldolor, and RediTrex, along with pipeline products [45] Question: What is the expected growth rate for the company? - Management refrained from providing specific guidance but indicated that pipeline products could lead to significant future growth [47] Question: What is included in the non-current inventory? - Non-current inventory primarily consists of API and work in process inventory for Vibativ, expected to be used over multiple years [49] Question: Plans to reduce high inventory levels? - Management acknowledged the need to work down inventory acquired with Vibativ and plans to do so over time [51]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-33637 | --- | --- | |----------------------------------------------------------------------------------------|------------- ...

CUMBERLAND® PHARMACE UTICALS Corporate Presentation Nasdaq CPIX Safe Harbor Statement This presentation contains forward-looking statements concerning our approved products and product development, our technology, our competitors, our intellectual property, our financial condition and our plans for research and development programs that involve risks, uncertainties and assumptions. These statements are based on the current estimates and assumptions of the management of Cumberland Pharmaceuticals as of the d ...

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Q3 2020 Earnings Conference Call November 10, 2020 4:30 PM ET Company Participants Erin Gull - Senior Corporate Relations Associate A. J. Kazimi - Founder, Chairman, President & CEO Martin Cearnal - EVP, Chief Commercial Officer & Director Michael Bonner - CFO and Senior Director, Finance & Accounting Conference Call Participants James Terwilliger - Paulson Investment Company Operator Thank you for joining the Cumberland Pharmaceuticals Third Quarter 2020 Finan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-33637 | --- | --- | |---------------------------------------------------|------------------------------------------------------- ...